



9,500 Results

Any time ▾

ADA/JDRF Type 1 Diabetes Sourcebook, Excerpt #4 ...

www.diabetesincontrol.com › Resources › Clinical Gems ▾

Abdelghaffar S, Attia AM: **Metformin** added to **insulin** therapy for **type 1 diabetes** mellitus in adolescents. Cochrane Database Syst Rev CD006691, 2009 Vella S, Buetow L, Royle P, Livingstone S, Colhoun HM, Petrie JR: The use of metformin in **type 1 diabetes**: a systematic review of efficacy.

Physical Activity and Type 1 Diabetes

www.ncbi.nlm.nih.gov › ... › J Diabetes Sci Technol › v.9(3); 2015 May

Jan 06, 2015 · De Leeuw I, Vague P, Selam JL, et al. **Insulin** detemir used in **basal-bolus therapy** in people with **type 1 diabetes** is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH **insulin**.

Cited by: 24

Author: Sheri R. Colberg, Remmert Laan, Eyal Da...

Publish Year: 2015

Physiology of Managing T1D | Insulin Nation

<https://insulinnation.com/treatment/physiology-of-managing-t1d> ▾

Historically, **Type 1 diabetes** was incurable and eventually led to death, with the only effective treatment a no-carbohydrate diet that was impossible to maintain. In 1921 Frederic Banting and John Macleod, with the help of Charles Best, investigated the pancreatic ducts of healthy dogs and in December 1921 obtained from their islets of Langerhans a saline extract that kept a severely diabetic dog alive.

[PDF] Leptin for type 1 diabetes: coming onto stage to be (or ...

deepblue.lib.umich.edu/.../j.1399-5448.2011.00797.x.pdf?sequence=1 ▾

role for the **treatment** of **Type 1 diabetes**. In this review we discuss the positive ... Exactly 72years after the discovery of **insulin**, a hormone that offered life full of potential to all ... support to exploration of leptin as an **adjunctive therapy** for patients suffering from **type 1 diabetes**. I will

Name of Journal: *World Journal of Diabetes*

Manuscript NO: 46796

Manuscript Type: EDITORIAL

Pharmacologic adjunctive to insulin therapies in type 1 diabetes: The journey has just begun

Spyridon N Karras, Theocharis Koufakis, Pantelis Zebekakis, Kalliopi Kotsa

Abstract

Treatment of Type 1 Diabetes (T1D) is currently based exclusively on insulin replacement therapy. However, there is a need for better glycemic control, lower hypoglycemia rates, more effective weight management, and further reduction of cardiovascular risk in people with T1D. In this context, agents from the pharmaceutical quiver of Type 2 Diabetes are being tested in clinical trials, as adjunctive to insulin therapies for T1D patients. Despite the limited amount of relevant evidence and the inter-class variability, it can be said that these agents have a role in optimizing metabolic control, assisting weight management and reducing glycemic variability in people with T1D. Specific safety issues, including the increased risk of hypoglycemia and diabetic ketoacidosis, as well as the effects of these treatments on major cardiovascular outcomes should be further assessed by future studies, before these therapeutic choices become widely available for T1D management.

Match Overview

1 Internet 17 words
crawled on 26-Sep-2018
www.cvdreal.com

1%



国内版

国际版

Pharmacologic adjunctive to insulin therapies in type 1 diabetes: The journey has



All

Images

Videos

翻译成中文

关闭取词

12,100 Results

Any time ▾

Pharmacology - DM - Day 3 - Oral Agents Flashcards | Quizlet

<https://quizlet.com/11272893/pharmacology-dm-day-3-oral-agents...> ▾

Pharmacology - DM - Day 3 - Oral Agents. STUDY. PLAY. Oral Agents. Biguanides Sulfonylureas Meglitinides ... **Adjunctive therapy** in patients with **type 2 diabetes** who are taking metformin, a sulfonylurea, TZD or a combination of the above but have not achieved adequate glycemic control ... ABs HgA1c **has begun** to increase over the past year and is ...

Stopping Type 1 Diabetes: Attempts to Prevent or Cure Type ...

www.ncbi.nlm.nih.gov › ... › **Diabetes** › v.60(1); 2011 Jan

Stopping immune destruction of β -cells. The ability to predict type 1 diabetes on the basis of immunologic, genetic, and metabolic markers has led to several large studies designed to determine whether type 1 diabetes can be prevented by intervening in individuals with identified autoimmunity (Fig. 2).

Cited by: 115

Author: Jay S. Skyler, Camillo Ricordi

Publish Year: 2011

Primary and secondary prevention of Type 1 diabetes

www.ncbi.nlm.nih.gov › Journal List › HHS Author Manuscripts

Type 1 Diabetes TrialNet also **has just** embarked on a randomized placebo-controlled trial with the co-stimulation blocker abatacept to determine whether this can delay or prevent **Type 1 diabetes** in relatives at risk of **Type 1 diabetes** . Enrolment criteria include two **diabetes** autoantibodies and a normal oral glucose tolerance test.

Cited by: 85

Author: J. S. Skyler

Publish Year: 2013

New Potential Adjuncts to Treatment of Children With Type ...